Advertisement

In Vitro Detection of Cellular Adjuvant Properties of Human Invariant Natural Killer T Cells

  • Rong Zhang
  • Shuichi Kitayama
  • Tianyi Liu
  • Norihiro Ueda
  • Yumi Tokumitsu
  • Hiroaki Mashima
  • Hideki Ohdan
  • Shin Kaneko
  • Yasushi Uemura
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2048)

Abstract

Invariant natural killer T (iNKT) cells are a subset of T lymphocytes that play a crucial role in the tumor surveillance. The activation of iNKT cells by their specific ligand α-galactosylceramide (α-GalCer) induces the activation of dendritic cells (DCs) via reciprocal interaction, which results in the generation of cellular immunity against cancer. Here we describe a method to detect DC-mediated cellular adjuvant properties of human iNKT cells in vitro.

Key words

Invariant natural killer T cells Dendritic cells T lymphocytes Cellular adjuvant Cancer immunotherapy 

Notes

Acknowledgments

This study was supported by grants from the Grants-in-Aid 17K10717 and 17K10806 from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; the National Cancer Center Research and Development Fund (28-A-8); and the Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development (AMED 15ck0196002h0103). We thank Mrs. M. Ozaki and K. Kobayashi (National Cancer Center) for secretarial support.

References

  1. 1.
    Bendelac A, Savage PB, Teyton L (2007) The biology of NKT cells. Annu Rev Immunol 25:297–336.  https://doi.org/10.1146/annurev.immunol.25.022106.141711CrossRefPubMedGoogle Scholar
  2. 2.
    Molling JW, Moreno M, van der Vliet HJ, van den Eertwegh AJ, Scheper RJ, von Blomberg BM, Bontkes HJ (2008) Invariant natural killer T cells and immunotherapy of cancer. Clin Immunol 129:182–194.  https://doi.org/10.1016/j.clim.2008.07.025CrossRefPubMedGoogle Scholar
  3. 3.
    Fujii S, Shimizu K, Kronenberg M, Steinman RM (2002) Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3(9):867–874.  https://doi.org/10.1038/ni827CrossRefPubMedGoogle Scholar
  4. 4.
    Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T (1999) The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 189(7):1121–1128CrossRefGoogle Scholar
  5. 5.
    Motohashi S, Nakayama T (2009) Invariant natural killer T cell-based immunotherapy for cancer. Immunotherapy 1(1):73–82.  https://doi.org/10.2217/1750743x.1.1.73CrossRefPubMedGoogle Scholar
  6. 6.
    Fujii SI, Shimizu K (2017) Exploiting antitumor immunotherapeutic novel strategies by deciphering the cross talk between invariant NKT cells and dendritic cells. Front Immunol 8:886.  https://doi.org/10.3389/fimmu.2017.00886CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Liu H, Chen L, Liu J, Meng H, Zhang R, Ma L, Wu L, Yu S, Shi F, Li Y, Zhang L, Wang L, Feng S, Zhang Q, Peng Y, Wu Q, Liu C, Chang X, Yang L, Uemura Y, Yu X, Liu T (2017) Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma. Cancer Lett 411:182–190.  https://doi.org/10.1016/j.canlet.2017.09.022CrossRefPubMedGoogle Scholar
  8. 8.
    Nair S, Dhodapkar MV (2017) Natural killer T cells in Cancer immunotherapy. Front Immunol 8:1178.  https://doi.org/10.3389/fimmu.2017.01178CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Krijgsman D, Hokland M, Kuppen PJK (2018) The role of natural killer T cells in cancer—a phenotypical and functional approach. Front Immunol 9:367.  https://doi.org/10.3389/fimmu.2018.00367CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gasser O, Sharples KJ, Barrow C, Williams GM, Bauer E, Wood CE, Mester B, Dzhelali M, Caygill G, Jones J, Hayman CM, Hinder VA, Macapagal J, McCusker M, Weinkove R, Painter GF, Brimble MA, Findlay MP, Dunbar PR, Hermans IF (2018) A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and alpha-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients. Cancer Immunol Immunother 67(2):285–298.  https://doi.org/10.1007/s00262-017-2085-9CrossRefPubMedGoogle Scholar
  11. 11.
    Lameris R, Schneiders FL, de Gruijl TD, van der Vliet HJ (2014) Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines. Methods Mol Biol 1139:155–165.  https://doi.org/10.1007/978-1-4939-0345-0_14CrossRefPubMedGoogle Scholar
  12. 12.
    Gottschalk C, Mettke E, Kurts C (2015) The role of invariant natural killer T cells in dendritic cell licensing, cross-priming, and memory CD8(+) T cell generation. Front Immunol 6:379.  https://doi.org/10.3389/fimmu.2015.00379CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Keller CW, Freigang S, Lunemann JD (2017) Reciprocal crosstalk between dendritic cells and natural killer T cells: mechanisms and therapeutic potential. Front Immunol 8:570.  https://doi.org/10.3389/fimmu.2017.00570CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Liu TY, Uemura Y, Suzuki M, Narita Y, Hirata S, Ohyama H, Ishihara O, Matsushita S (2008) Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells. Eur J Immunol 38(4):1012–1023.  https://doi.org/10.1002/eji.200737838CrossRefPubMedGoogle Scholar
  15. 15.
    Uemura Y, Liu TY, Narita Y, Suzuki M, Nakatsuka R, Araki T, Matsumoto M, Iwai LK, Hirosawa N, Matsuoka Y, Murakami M, Kimura T, Hase M, Kohno H, Sasaki Y, Ichihara Y, Ishihara O, Kikuchi H, Sakamoto Y, Jiao SC, Senju S, Sonoda Y (2009) Cytokine-dependent modification of IL-12p70 and IL-23 balance in dendritic cells by ligand activation of Valpha24 invariant NKT cells. J Immunol 183(1):201–208.  https://doi.org/10.4049/jimmunol.0900873CrossRefPubMedGoogle Scholar
  16. 16.
    Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D, Nakayama-Hosoya K, Iriguchi S, Uemura Y, Shimizu T, Takayama N, Yamada D, Nishimura K, Ohtaka M, Watanabe N, Takahashi S, Iwamoto A, Koseki H, Nakanishi M, Eto K, Nakauchi H (2013) Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12(1):114–126.  https://doi.org/10.1016/j.stem.2012.11.002CrossRefPubMedGoogle Scholar
  17. 17.
    Kitayama S, Zhang R, Liu TY, Ueda N, Iriguchi S, Yasui Y, Kawai Y, Tatsumi M, Hirai N, Mizoro Y, Iwama T, Watanabe A, Nakanishi M, Kuzushima K, Uemura Y, Kaneko S (2016) Cellular adjuvant properties, direct cytotoxicity of re-differentiated Valpha24 invariant NKT-like cells from human induced pluripotent stem cells. Stem cell reports 6(2):213–227.  https://doi.org/10.1016/j.stemcr.2016.01.005CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Yamada D, Iyoda T, Vizcardo R, Shimizu K, Sato Y, Endo TA, Kitahara G, Okoshi M, Kobayashi M, Sakurai M, Ohara O, Taniguchi M, Koseki H, Fujii SI (2016) Efficient regeneration of human Valpha24(+) invariant natural killer T cells and their anti-tumor activity in vivo. Stem Cells 34(12):2852–2860.  https://doi.org/10.1002/stem.2465CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Rong Zhang
    • 1
    • 2
  • Shuichi Kitayama
    • 3
  • Tianyi Liu
    • 4
  • Norihiro Ueda
    • 1
    • 2
    • 3
  • Yumi Tokumitsu
    • 1
  • Hiroaki Mashima
    • 5
  • Hideki Ohdan
    • 5
  • Shin Kaneko
    • 3
  • Yasushi Uemura
    • 1
    • 2
  1. 1.Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial CenterNational Cancer CenterKashiwaJapan
  2. 2.Division of ImmunologyAichi Cancer Center Research InstituteNagoyaJapan
  3. 3.Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA)Kyoto UniversityKyotoJapan
  4. 4.Key Laboratory of Cancer CenterChinese PLA General HospitalBeijingChina
  5. 5.Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health SciencesHiroshima UniversityHiroshimaJapan

Personalised recommendations